id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-271764-um001ffd	Garraud, Olivier	Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?	2020-06-27		.txt	text/plain	1306	70	46	It is obvious that ethically sound, quality reviewed, well conducted clinical trials are essential to situate convalescent plasma therapy among the therapeutic arsenal to treat SARS-Cov-2 infection. Indeed, since the discovery of numerous thrombotic complications among the severe presentations of COVID-19 [18] [19] [20] , it cannot be excluded that normal plasma factors resolve the DIC-like symptomatology or counteract the effects of lupus-like antibodies, or sooth the blood vessel endothelium if the disease associates to endotheliopathy (as was seen relative to Ebola-virus infection and convalescent plasma therapy [21] ). Further, what about the ethics of transfusing supposedly large volumes of non-specific plasma as a control to a person in danger of developing severe complications of SARS-Cov-2? Clinical trials to evaluate the quality, the efficacy and the safety of convalescent plasma therapy as soon as possible after the onset of an epidemic threat would be mostly valuable.	./cache/cord-271764-um001ffd.txt	./txt/cord-271764-um001ffd.txt